Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies. (Q52385885)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 1994

Language	Label	Description	Also known as
English	Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.	scientific article published in January 1994

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

M V Dhodapkar

1

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

R L Richardson

2

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

J M Reid

3

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

M M Ames

4

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

publication date

1 January 1994

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

12

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

3

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

207-216

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro and in vivo evaluation of US-NCI compounds in human tumor xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinetics of pharmacologic response I. Proposed relationships between response and drug concentration in the intact animal and man

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamics in cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis, chemical stability and pre-clinical anti-tumor activity of pyrazine diazohydroxide, sodium salt (NSC-361456)

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gas chromatographic assay for the new antitumor agent pyrazine-2-diazohydroxide (diazohydroxide) and its stability in buffer, blood and plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Some suggestions for measuring predictive performance

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7896539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00873961

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 April 2018

http://europepmc.org/abstract/MED/7896539

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52385885&oldid=2211603290"